Lance v. Wyeth (majority)Annotate this Case
In a products liability matter, the issue before the Supreme Court was whether under Pennsylvania law a pharmaceutical company was immune from responding in damages for a lack of due care resulting in injury or death except for two discrete grounds: drug impurities or deficient warnings. Appellee made her primary claim against the makers of "phen-fen" as one of "negligence - unreasonable marketing of a dangerous rug and unreasonable failure to remove the drug from the market before 1997." The manufacturer moved for summary judgment, arguing that the appellee failed to assert a cognizable cause of action. The court of common please granted the company's motion. The Superior Court reversed, and both parties appealed, challenging respectively the Superior Court's holdings that pharmaceutical companies were not immune from claims of negligent drug design, and that claims of negligent marketing, testing, and failure of remove the drugs from the market were unviable claims. The Supreme Court affirmed in part, reversed in part, and remanded for further proceedings: "there has been no supported presentation here which would persuade us to immunize companies from the responsibility to respond in damages for such a lack of due care resulting in personal injury or death."